Precision BioSciences (NASDAQ:DTIL) Rating Reiterated by HC Wainwright

Precision BioSciences (NASDAQ:DTIL - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 421.29% from the company's current price.

Precision BioSciences Stock Down 10.6 %

Precision BioSciences stock traded down $1.36 during mid-day trading on Wednesday, hitting $11.51. 221,806 shares of the company's stock traded hands, compared to its average volume of 130,623. The firm has a 50 day moving average price of $13.02 and a 200 day moving average price of $11.75. The company has a market cap of $79.65 million, a PE ratio of -0.72 and a beta of 1.53. Precision BioSciences has a one year low of $8.25 and a one year high of $28.44.

Insider Transactions at Precision BioSciences

In other news, CEO Michael Amoroso sold 4,579 shares of the business's stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $10.80, for a total value of $49,453.20. Following the sale, the chief executive officer now owns 11,881 shares of the company's stock, valued at approximately $128,314.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 6,005 shares of company stock valued at $64,854. Corporate insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Balyasny Asset Management LLC raised its position in shares of Precision BioSciences by 70.1% during the third quarter. Balyasny Asset Management LLC now owns 19,333 shares of the company's stock worth $25,000 after purchasing an additional 7,967 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Precision BioSciences by 235.6% during the third quarter. Tower Research Capital LLC TRC now owns 25,647 shares of the company's stock worth $34,000 after purchasing an additional 18,005 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Precision BioSciences during the first quarter worth $34,000. Citigroup Inc. acquired a new stake in shares of Precision BioSciences during the first quarter worth $35,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Precision BioSciences during the first quarter worth $35,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.